Abstract 936P
Background
The ADAURA study opens the door for precision medicine and biomarker testing to enter the early stage of non-small cell lung cancer (NSCLC), that is, the precise decision-making of postoperative adjuvant therapy for early-stage. As previously reported, NSCLC patients with different EGFR mutants display heterogeneous clinical course and their different response to EGFR-TKIs, but weather their responses to adjuvant chemotherapy are various is still unclear.
Methods
Herein, based on precision molecular testing through NGS and data analysis of 336 Chinese primary NSCLC patients, and postoperative follow-up data of 131 patients with EGFR mutation who accepted surgery and postoperative adjuvant chemotherapy, we tried to demonstrate the different clinical benefit in postoperative adjuvant chemotherapy. Accurately determine the lymph node metastasis status of patients before surgery, which can adjust the patient's treatment plan as soon as possible, manage patients by stratification, and monitor the disease progress of patients in real time. This study found that immune cells in the tumor microenvironment of colorectal cancer patients have the efficacy of real-time judgment and prediction of lymph node metastasis in patients with colorectal cancer, so they can be used as biomarkers for early and precise management of patient prognosis, treatment decision-making and improvement of patient survival.
Results
Among 131 EGFR mutated NSCLC patients, 38 (29.01%) patients carried mutation of EGFR exon 19 deletion, 69 (59.67%) patients were EGFR L858R mutation, and 24 (18.32%) were ERFR uncommon mutations. The median follow-up was 11.27 months. Analysis of progression-free survival revealed that, in patient with EGFR exon 19 deletion mutation, adjuvant, better PFS was showed in cohort with adjuvant chemotherapy, however, in patients with EGFR L8585R mutation and EGFR uncommon mutation, adjuvant chemotherapy did not improve PFS.
Conclusions
These results suggest that patients with different EGFR mutations need to be treated differently, as well as choice of adjuvant chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.